ETRA

8.2807.38%
NE

Nancy E. Stagliano

Independent Chair

Dr. Nancy E. Stagliano, Ph. D. CA, was Executive Chair at STAR Therapeutics Inc. since March 2019 until 2026 and serves as Director from 2026. She served as Director since November 2024 until 2025 and was the Chairman of the Board of Latigo Biotherapeutics, Inc. since February 2024 until November 2024. She has been Board Chair and Chief Executive Officer at Neuron23, Inc. She serves as Director at Pancreatic Cancer Action Network, Inc. since August 2020. She served as Member of Advisory Board at Swift Health Systems Inc. until 2022. She has experience in the biotechnology industry, her career path has always stayed close to the science, beginning with Millennium Pharmaceuticals in Cambridge, MA, in the discovery organization. She also serves as a Director of the not-for-profit Board of PanCAN. She has also advised venture capital firms Westlake Village BioPartners and New Leaf Ventures. She serves as Independent Chair at Electra Therapeutics, Inc. and serves as its Executive Chair and its Director since March 2019. She is a Venture Partner at New Leaf Venture Partners. She serves as a Director at Pandion Therapeutics, Inc. (formerly known as Pandion Therapeutics Holdco LLC) since July 2018 and serves as its lead Independent Director. She served as the Chief Executive Officer and President at Bioverativ USA Inc. She served as the Chief Executive Officer at iPierian, Inc. since September 07, 2011 April 2014. Dr. Stagliano served as Consultant of CytomX Therapeutics, Inc. she was Founder and Chief Executive Officer of True North Therapeutics, Incorporated from August 2013 until June 2017. She has an accomplished career as a Biotech Leader spanning all aspects of the industry, from discovery research and strategy to global medical affairs and corporate communications. Prior to iPierian, she served as Chief Executive Officer of CytomX Therapeutics Inc. since February 2008, where she co-founded and was a Lead Inventor on the patents for its Probody platform. She served as the Chief Operating Officer of CytomX LLC, which launched CytomX Therapeutics as well as LungLife AI, Inc. Before moving to California, Dr. Stagliano joined Cambridge, Massachusetts, biotechnology industry in the late 1990s, where she had tenure at Millennium Pharmaceuticals and consulted to several local startups. She served as Independent Director of Pandion Operations, Inc. (formerly known as Pandion Therapeutics, Inc.) She served as a Director at Bioverativ USA Inc. She served as a Member of Scientific Advisory Board at LungLife AI, Inc. She served as a Director of biOasis Technologies Inc. since September 21, 2017 until November 2019. She served as a Director of iPierian, Inc. She serves as Member of Scientific Advisory Board at ADRx, Inc. She served as Director and Member of scientific advisory Board at CytomX Therapeutics, Inc. She served as an independently-funded Research Fellow at the Massachusetts General Hospital and Harvard Medical School, where she studied Mechanisms of brain injury after stroke. Dr. Stagliano has BS in Electrical Engineering and MS in Biomedical Engineering, both from Drexel University in Philadelphia. She obtained her PhD in Neuroscience from the University of Miami, school of Medicine.

Positions